risperidone has been researched along with Gynecomastia in 19 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Gynecomastia: Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This open-label, prospective, 4-month study in hyperprolactinemic patients with schizophrenia explored whether prolactin levels decrease after switching antipsychotic therapy to olanzapine." | 9.12 | Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. ( Ahl, J; Kinon, BJ; Liu-Seifert, H; Maguire, GA, 2006) |
| "The purpose of this study was to quantify the risk of gynecomastia with risperidone in adolescent and young adult males." | 7.81 | Risperidone and Risk of Gynecomastia in Young Men. ( Brophy, JM; Carleton, B; Etminan, M, 2015) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 7.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "Risperidone is associated with hyperprolactinemia and its consequent symptoms such as gynecomastia, galactorrhea and sexual dysfunction in adults, and less so in adolescents." | 7.77 | Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination. ( Praharaj, SK; Pratheesh, PJ; Srivastava, A, 2011) |
| "Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea." | 7.73 | Risperidone-induced symptomatic hyperprolactinaemia in adolescents. ( Eap, CB; Holzer, L, 2006) |
| "This open-label, prospective, 4-month study in hyperprolactinemic patients with schizophrenia explored whether prolactin levels decrease after switching antipsychotic therapy to olanzapine." | 5.12 | Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. ( Ahl, J; Kinon, BJ; Liu-Seifert, H; Maguire, GA, 2006) |
| "The purpose of this study was to quantify the risk of gynecomastia with risperidone in adolescent and young adult males." | 3.81 | Risperidone and Risk of Gynecomastia in Young Men. ( Brophy, JM; Carleton, B; Etminan, M, 2015) |
| "Hyperprolactinemia is a common side effect in young males treated over the long term with risperidone." | 3.78 | Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. ( Boot, AM; Buitelaar, JK; Roke, Y; Tenback, D; van Harten, PN, 2012) |
| "Risperidone is associated with hyperprolactinemia and its consequent symptoms such as gynecomastia, galactorrhea and sexual dysfunction in adults, and less so in adolescents." | 3.77 | Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination. ( Praharaj, SK; Pratheesh, PJ; Srivastava, A, 2011) |
| "Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea." | 3.73 | Risperidone-induced symptomatic hyperprolactinaemia in adolescents. ( Eap, CB; Holzer, L, 2006) |
| " Risperidone had the highest adjusted reporting ratios for hyperprolactinemia (EBGM 34." | 3.73 | Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. ( Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM, 2006) |
| "To review the evidence concerning treatment-related gynecomastia in patients taking spironolactone, antiandrogens, 5 alpha-reductase inhibitors, lipid-lowering and psychotropic drugs." | 2.72 | Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials. ( Magri, V; Montanari, E; Perletti, G; Stamatiou, K; Trinchieri, A; Trinchieri, M, 2021) |
| " In addition, adverse events were also evaluated." | 1.34 | [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Trinchieri, A | 1 |
| Perletti, G | 1 |
| Magri, V | 1 |
| Stamatiou, K | 1 |
| Trinchieri, M | 1 |
| Montanari, E | 1 |
| Eugene, AR | 2 |
| Eugene, B | 2 |
| Etminan, M | 2 |
| Heran, B | 1 |
| Carleton, B | 2 |
| Brophy, JM | 2 |
| Koplewicz, HS | 1 |
| Findling, RL | 1 |
| Daneman, D | 1 |
| Dyer, O | 1 |
| Emsley, R | 1 |
| Oosthuizen, P | 1 |
| Koen, L | 1 |
| Niehaus, DJ | 1 |
| Medori, R | 1 |
| Rabinowitz, J | 1 |
| Pratheesh, PJ | 1 |
| Praharaj, SK | 1 |
| Srivastava, A | 1 |
| Roke, Y | 1 |
| Buitelaar, JK | 1 |
| Boot, AM | 1 |
| Tenback, D | 1 |
| van Harten, PN | 1 |
| Lambert, M | 1 |
| Haro, JM | 1 |
| Novick, D | 1 |
| Edgell, ET | 1 |
| Kennedy, L | 1 |
| Ratcliffe, M | 1 |
| Naber, D | 1 |
| Mendhekar, DN | 1 |
| Andrade, CR | 1 |
| Kinon, BJ | 1 |
| Ahl, J | 1 |
| Liu-Seifert, H | 1 |
| Maguire, GA | 1 |
| Holzer, L | 1 |
| Eap, CB | 1 |
| Szarfman, A | 1 |
| Tonning, JM | 1 |
| Levine, JG | 1 |
| Doraiswamy, PM | 1 |
| István, S | 1 |
| Agoston, T | 1 |
| Tamás, T | 1 |
| Zoltán, J | 1 |
| Shiwach, RS | 1 |
| Carmody, TJ | 1 |
| Benazzi, F | 1 |
| Dartnall, NA | 1 |
| Holmes, JP | 1 |
| Morgan, SN | 1 |
| McDougle, CJ | 1 |
1 review available for risperidone and Gynecomastia
| Article | Year |
|---|---|
Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials.
Topics: Antipsychotic Agents; Gynecomastia; Humans; Male; Pharmaceutical Preparations; Randomized Controlled | 2021 |
1 trial available for risperidone and Gynecomastia
| Article | Year |
|---|---|
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Estradiol; Female; Galactorrhea; Gynecomastia; H | 2006 |
17 other studies available for risperidone and Gynecomastia
| Article | Year |
|---|---|
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Biomarkers; Child; Child, Preschool; Databases, | 2018 |
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Biomarkers; Child; Child, Preschool; Databases, | 2018 |
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Biomarkers; Child; Child, Preschool; Databases, | 2018 |
An opportunity for clinical pharmacology trained physicians to improve patient drug safety: A retrospective analysis of adverse drug reactions in teenagers.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Biomarkers; Child; Child, Preschool; Databases, | 2018 |
Risperidone use and risk for gynecomastia in men.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Case-Control Studies; Databases, Factual; Gyne | 2014 |
Risperidone and Risk of Gynecomastia in Young Men.
Topics: Adolescent; Adult; Antipsychotic Agents; Case-Control Studies; Gynecomastia; Humans; Male; Risk; Ris | 2015 |
From the Editor-in-Chief's Desk.
Topics: Bipolar Disorder; Depression; Gynecomastia; Humans; Mental Processes; Quetiapine Fumarate; Reward; R | 2015 |
Prolactin Levels During Long-Term Risperidone Treatment in Children and Adolescents: a reanalysis of data.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Data I | 2016 |
Johnson & Johnson is ordered to pay $70m to boy who developed gynecomastia.
Topics: Antipsychotic Agents; Compensation and Redress; Drug Labeling; Gynecomastia; Humans; Legislation, Dr | 2016 |
Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-B | 2008 |
Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.
Topics: Drug Therapy, Combination; Fluvoxamine; Galactorrhea; Gynecomastia; Humans; Male; Obsessive-Compulsi | 2011 |
Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; | 2012 |
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.
Topics: Adult; Ambulatory Care; Amenorrhea; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapin | 2005 |
Unilateral gynecomastia induced by risperidone in a geriatric male patient.
Topics: Aged; Antipsychotic Agents; Gynecomastia; Humans; Male; Risperidone | 2005 |
Risperidone-induced symptomatic hyperprolactinaemia in adolescents.
Topics: Adolescent; Antipsychotic Agents; Drug Monitoring; Female; Galactorrhea; Gynecomastia; Humans; Hyper | 2006 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; | 2006 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzo | 2007 |
Prolactogenic effects of risperidone in male patients--a preliminary study.
Topics: Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedul | 1998 |
Gynecomastia with risperidone-fluoxetine combination.
Topics: Adult; Antipsychotic Agents; Drug Combinations; Fluoxetine; Gynecomastia; Humans; Male; Psychiatric | 1999 |
Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism.
Topics: Adult; Autistic Disorder; Compulsive Behavior; Dopamine Antagonists; Female; Gynecomastia; Humans; I | 1999 |